17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models

Anti-Cancer Drugs

Volumn 15, Issue 4, 2004, Pages 377-387

  Burger, Angelika M ^a   Fiebig, Heinz Herbert ^a   Stinson, Sherman F ^b   Sausville, Edward A ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ansamycin; c Raf 1; Cancer treatment; Hsp90; Melanoma

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; MAXIMUM TOLERATED DOSE; MELANOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; INJECTIONS, INTRAPERITONEAL; LACTAMS, MACROCYCLIC; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-RAF; RIFABUTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 1942485334     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200404000-00011     Document Type: Article

References (33)

1. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anticancer agent: its molecular target and biochemical activity. Invest New Drugs 1999; 17:361-373.
2. Supko JG, Hichman RL, Frever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36:305-315.
3. Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J, et al. Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats. Proc Am Ass Cancer Res 1997; 38:308.
4. Schnur RC, Corman ML, Gallachun RJ, Cooper BA, Dee MF, Coty JL, et al. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995; 38:3813-3820.
5. Developmental Therapeutics Program Website: http://dtp.nci.nih.gov/, mean graph for compound S330507.
6. Eiseman JL, Sentz DL, Zuhowski EG, Ramsland TS, Rosen DM, Reyna SP, et al. Plasma pharmacokinetics and tissue distribution of 17-allylaminogeldanamycin (NSC 330507), a prodrug for geldanamycin, in CD2F1 mice and Fischer 344 rats. Proc Am Ass Cancer Res 1997; 38:308.
7. Eiseman J, Grimm A, Sentz D, Lessor T, Gessner R, Zuhowski E, et al. A. Pharmacokinetics of 17-allylamino(17-demethoxy)geldanamycin in SCID mice bearing MDA-MB-453 xenografts and alterations in the expression of p185erb-B2 in the xenografts following treatment. Clin Cancer Res 1999; 5:3837s.
8. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89:239-250.
9. Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, et al. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced her-2/neu activation, receptor expression and proliferation of her-2-positive malignant cells. Int J Cancer 1997; 70:221-229.
10. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995; 270:24585-24588.
11. vsrc heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91:8324-8328.
12. Whitesell L, Sutphin PD, Pulcini EJ, Martinex JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998; 18:1517-1524.
13. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Quellette M, et al. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 1999; 13:817-826.
14. Fiebig HH, Berger DP, Dengler WA, Wallbrecher E, Winterhalter BR. Combined in vitro/in vivo test procedure with human tumor xenografts. In: Fiebig HH, Berger DP (editors): Immunodeficient Mice in Oncology. Basel: Karger; 1992, pp. 321-351.
15. Roth T, Burger AM, Dengler W, Fiebig HH, Monks A, McMahon J, et al. Human tumor cell lines demonstrating the characteristics of patient tumors as useful models for anticancer drug development. In: Fiebig HH, Burger AM (editors): Relevance of Tumor Models for Anticancer Drug Development. Basel: Karger; 1999, pp. 145-156.
16. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
17. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197:461-463.
18. Phillips RM, Burger AW, Jarrett C, Loadman PM, Fiebig HH. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme directed bioreductive drug development. Cancer Res 2000; 60:6384-6390.
19. Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH. Preclinical evaluation of a methotrexate-albumine-conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer 2001; 92:718-24.
20. Stinson SF, House T, Bramhall C, Saavedra JE, Keefer LK, Nims RW. Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. Xenobiotica 2002; 32:339-347
21. Burck CH. Histologische Technik. Stuttgart: Thieme; 1988.
22. Mukherjee P, Sotnikov V, Mangian HJ, Zhou J-R, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst, 1999; 91: 512-523.
23. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-234.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
25. + lymphoma cells by the Hsp90 antagonist 17-allylamino,17- demethoxygeldanamycin. Cancer Res 2002; 62:1559-1566.
26. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17 demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61:1799-1804.
27. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003; 63:2139-2144.
28. Bagatell R, Khan O, Paine-Marrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001; 7:2076-2084.
29. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425:407-410.
30. Banjeri U, O'Donnell A, Scurr M, Benson C, Hanwell J, Clark S, et al. Phase I trial of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17aag). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc Am Soc Clin Oncol 2001; 20:82a.
31. Wilson RH, Takimoto CH, Agnew EB, Morrison G, Grollman F, Thomas RR, et al. Phase I pharmacological study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001; 20:82a.
32. Münster PN, Tong W, Schwartz L, Larson S, Keneson K, De La Cruz A, et al. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (pts) with advanced solid malignancies. Proc Am Soc Clin Oncol 2001; 20:83a.
33. Banerji U, Clake P, Walton M, O'Donnel A, Raynaud F, Turner A, et al. Preclinical an clinical activity of the molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin(17AAG) in malignant melanoma. Proc Am Ass Cancer Res 2003; 44:677 (abstr 2966).